A Phase 3 interventional study of Tislelizumab and Durvalumab in Non Small Cell Lung Cancer, sponsored by BeiGene. Terminated at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 28 · Phase 3 10 · Phase 4 2
First in 2017; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 41 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines: none open now, 1 under way, 1 of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 7th registered.
BeOne Medicines’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2017.
2 of the studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07320105Fujian Cancer HospitalPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | 2027-01-15 |
| NCT07845916Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among BeOne Medicines’s 16 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.
The study initiated with Protocol Amendment 1.0 (PA 1; dated on 16 April 2021). In April 2022 Protocol Amendment 2 (PA 2) was implemented. In PA 1, participants with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC and evaluable PD-L1 expression all comers were enrolled; cCRT was given within the study. In PA 2, the enrollment of the target population was revised into participants with unresectable locally advanced NSCLC whose disease has not progressed after definitive, platinum-based cCRT and with PD-L1 expression on ≥ 1% of tumor cells as assessed by the central lab; cCRT was given outside of the study.
After implementation of PA 2, participants who were randomized under PA 1 were given the option to continue assigned study treatment or to discontinue assigned treatment and begin standard of care treatment outside of the study. Participants enrolled under PA 1 were excluded from the primary and secondary analysis specified by PA 2.
This study was subsequently terminated by the Sponsor prior to enrollment of any participants under PA 2.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Antiviral therapy is permitted for participants with chronic virus (HBV) or virus (HCV) infection.
NOTE: Other protocol Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled under PA1 recieved two cycles of ociperlimab combined with tislelizumab and cCRT, followed by ociperlimab combined with tislelizumab up to 1 year after the cCRT phase
Drug: Tislelizumab · Drug: Ociperlimab · Drug: Chemotherapy · Radiation: Radiotherapy
Participants enrolled under PA1 recieved two cycles of tislelizumab combined with cCRT, followed by tislelizumab up to 1 year after the cCRT phase
Drug: Tislelizumab · Drug: Chemotherapy · Radiation: Radiotherapy
Participants enrolled under PA1 recieved two cycles of cCRT, followed by durvalumab to 1 year after the cCRT phase
Drug: Durvalumab · Drug: Chemotherapy · Radiation: Radiotherapy
200 mg intravenously every three weeks
Also known as: BGB-A317
10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
900 milligrams (mg) intravenously every three weeks
Also known as: BGB-A1217
The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options: * Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days. * Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously. * Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. * Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. The pemetrexed plus platinum regimen was only for participants with non-squamous histology.
Also known as: Concurrent Chemoradiotherapy (cCRT)
All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
Also known as: Concurrent Chemoradiotherapy (cCRT)
Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death, whichever occurred first.
Time frame: From randomization through to the end of study, planned duration was 20 months
Overall Survival (OS)
Defined as the time from the date of randomization until the date of death due to any cause
Time frame: From randomization through to the end of study, planned duration was 20 months
Overall Response Rate (ORR)
Defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) assessed by both the IRC and investigators per RECIST v1.1.
Time frame: From randomization through to the end of study, planned duration was 20 months
Duration of Response (DOR)
defined as the time from the first determination of a confirmed objective response assessed by both the IRC and investigators per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first
Time frame: From randomization through to the end of study, planned duration was 20 months
Time to Death or Distant Metastasis (TTDM) as Assessed by the Investigator
defined as the time from the date of randomization until the first date of distant metastasis assessed by both the IRC and investigators, or death. Distant metastasis is defined as any new lesion that is outside of the radiation field per RECIST v1.1 or proven by biopsy.
Time frame: From randomization through to the end of study, planned duration was 20 months
Progression-Free Survival 2 (PFS2)
defined as the time from randomization to the disease progression after next line of treatment, or death from any cause, whichever occurs first
Time frame: From randomization through to the end of study, planned duration was 20 months
Number of Participants Experiencing Adverse Events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Time frame: From first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever occured first; through study completion data cut-off date of October 17th, 2023 (maximum time on treatment was 16 months)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline and Cycle 6 (Each cycle is 21 days)
Change From Baseline in Health Related Quality of Life (HRQoL) as Assessed by Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
Change from baseline in QLQ-CL13 scores for coughing, dyspnea, and chest pain. The QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
Time frame: Baseline and Cycle 6 (Each cycle is 21 days)
Change From Baseline in Health Related Quality of Life (HRQoL) as Assessed by European Quality of Life-5 Dimensions (EQ-5D-5L)
The EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.
Time frame: Baseline and Cycle 6 (Each cycle is 21 days)
Serum Concentration of Ociperlimab
Serum concentrations of ociperlimab were measured for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date the investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1, 5 and EOT visit (Each Cycle was 21 days)
Serum Concentration of Tislelizumab for Participants in the Ociperlimab + Tislelizumab + cCRT Treatment Group
Serum concentrations of tislelizumab were collected for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (each cycle was 21 days)
Serum Concentration of Tislelizumab for Participants in the Tislelizumab + cCRT Treatment Group
Serum concentrations of tislelizumab were collected for participants in the Tislelizumab + cCRT treatment group at predose (within 60 minutes prior to infusion initiation) and postdose (within 30 minutes after the completion of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (Each Cycle is 21 days)
Immunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)
Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (ociperlimab and tislelizumab)
Time frame: Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days). Maximum number of treatment cycles was 19
Immunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)
Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (Ociperlimab + Tislelizumab + cCRT) and Arm B (Tislelizumab + cCRT)
Time frame: Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days, maximum number of treatment cycles was 19)
Programmed Death-Ligand 1 (PD-L1) and T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Expression in Archival and/or Fresh Tumor Tissues
Time frame: From randomization through to the end of study, planned duration was 20 months
Participants were enrolled in multiple study centers in Taiwan, China, Spain , United States, and Australia. The first participant was consented on June 17th, 2021, and the last participant completed on October 17th, 2023. The decision to terminate the study was made on July 11th, 2023.
| Milestone | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab |
|---|---|---|---|
| Started | 22 | 19 | 22 |
| Treated | 22 | 18 | 22 |
| Completed | 0 | 0 | 0 |
| Not completed | 22 | 19 | 22 |
| Withdrew: Study terminated by sponsor | 13 | 14 | 13 |
| Withdrew: Death | 8 | 4 | 8 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death, whichever occurred first.
No measurements were reported for this outcome.
Defined as the time from the date of randomization until the date of death due to any cause
No measurements were reported for this outcome.
Defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) assessed by both the IRC and investigators per RECIST v1.1.
No measurements were reported for this outcome.
defined as the time from the first determination of a confirmed objective response assessed by both the IRC and investigators per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first
No measurements were reported for this outcome.
defined as the time from the date of randomization until the first date of distant metastasis assessed by both the IRC and investigators, or death. Distant metastasis is defined as any new lesion that is outside of the radiation field per RECIST v1.1 or proven by biopsy.
No measurements were reported for this outcome.
defined as the time from randomization to the disease progression after next line of treatment, or death from any cause, whichever occurs first
No measurements were reported for this outcome.
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
| Participants | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab |
|---|---|---|---|
| TEAEs | 22 | 18 | 22 |
| SAEs | 11 | 8 | 8 |
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
No measurements were reported for this outcome.
Change from baseline in QLQ-CL13 scores for coughing, dyspnea, and chest pain. The QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
No measurements were reported for this outcome.
The EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.
No measurements were reported for this outcome.
Serum concentrations of ociperlimab were measured for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date the investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
| ug/ml | Ociperlimab + Tislelizumab + cCRT: Predose | Ociperlimab + Tislelizumab + cCRT: Postdose |
|---|---|---|
| Cycle 1 Day 1 | 18 ± NA | 312 ± 45.82 |
| Cycle 2 Day 1 | 34.54 ± 63.19 | — |
| Cycle 5 Day 1 | 74.86 ± 61.76 | 339.31 ± 38.21 |
| Cycle 9 Day 1 | 52.4 ± 82.40 | — |
| Cycle 17 Day 1 | 81.35 ± 53.83 | — |
| End of Treatment | — | 94.94 ± 232.05 |
Serum concentrations of tislelizumab were collected for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
| ug/mL | Ociperlimab + Tislelizumab + cCRT: Predose | Ociperlimab + Tislelizumab + cCRT: Postdose |
|---|---|---|
| Cycle 1 Day 1 | NA ± NA | 72.20 ± 26.27 |
| Cycle 2 Day 1 | 15.91 ± 78.83 | — |
| Cycle 5 Day 1 | 34.10 ± 49.67 | 97.08 ± 23.09 |
| Cycle 9 Day 1 | 30.22 ± 55.34 | — |
| Cycle 17 Day 1 | 32.24 ± 156.53 | — |
| End of Treatment | — | 49.55 ± 89.19 |
Serum concentrations of tislelizumab were collected for participants in the Tislelizumab + cCRT treatment group at predose (within 60 minutes prior to infusion initiation) and postdose (within 30 minutes after the completion of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.
| ug/mL | Tislelizumab: Predose | Tislelizumab: Postdose |
|---|---|---|
| Cycle 1 Day 1 | NA ± NA | 73.41 ± 18.53 |
| Cycle 2 Day 1 | 19.69 ± 27.01 | — |
| Cycle 5 Day 1 | 37.64 ± 47.00 | 100.26 ± 29.25 |
| Cycle 9 Day 1 | 36.98 ± 39.63 | — |
| Cycle 17 Day 1 | 41.29 ± 55.41 | — |
| End of Treatment | — | 40.18 ± 139.51 |
Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (ociperlimab and tislelizumab)
| Participants | Ociperlimab + Tislelizumab + cCRT |
|---|---|
| Immunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs) | 0 |
Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (Ociperlimab + Tislelizumab + cCRT) and Arm B (Tislelizumab + cCRT)
| Participants | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT |
|---|---|---|
| Immunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs) | 10 | 5 |
No measurements were reported for this outcome.
Collected over From first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever occured first; through study completion data cut-off date of October 17th, 2023 (maximum time on treatment was 16 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ociperlimab + Tislelizumab + cCRT | 8/22 (36.4%) | 11/22 (50%) | 22/22 (100%) |
| Tislelizumab + cCRT | 4/18 (22.2%) | 8/18 (44.4%) | 18/18 (100%) |
| cCRT Followed by Durvalumab | 8/22 (36.4%) | 8/22 (36.4%) | 22/22 (100%) |
| Event | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab |
|---|---|---|---|
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 3/22 | 2/18 | 0/22 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/22 | 2/18 | 0/22 |
| PneumoniaInfections and infestations | 2/22 | 1/18 | 1/22 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/22 | 1/18 | 2/22 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/22 | 0/18 | 0/22 |
| Lower respiratory tract infectionInfections and infestations | 0/22 | 1/18 | 0/22 |
| SinusitisInfections and infestations | 0/22 | 1/18 | 0/22 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 1/22 | 1/18 | 0/22 |
| HyponatraemiaMetabolism and nutrition disorders | 0/22 | 1/18 | 0/22 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/22 | 1/18 | 0/22 |
| Event | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab |
|---|---|---|---|
| White blood cell count decreasedInvestigations | 15/22 | 10/18 | 13/22 |
| AnaemiaBlood and lymphatic system disorders | 12/22 | 10/18 | 14/22 |
| Neutrophil count decreasedInvestigations | 14/22 | 5/18 | 13/22 |
| NauseaGastrointestinal disorders | 6/22 | 7/18 | 11/22 |
| Platelet count decreasedInvestigations | 8/22 | 5/18 | 10/22 |
| ConstipationGastrointestinal disorders | 9/22 | 5/18 | 8/22 |
| Radiation oesophagitisInjury, poisoning and procedural complications | 6/22 | 3/18 | 9/22 |
| Alanine aminotransferase increasedInvestigations | 8/22 | 0/18 | 6/22 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 5/22 | 6/18 | 7/22 |
| Decreased appetiteMetabolism and nutrition disorders | 7/22 | 5/18 | 7/22 |
The Intent-to-Treat (ITT) Analysis Set is defined as all randomized participants.
| Age, Continuous(years) | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab | Total |
|---|---|---|---|---|
| Mean | 63.4 ± 7.51 | 62.4 ± 9.27 | 64.1 ± 7.36 | 63.3 ± 7.93 |
| Sex: Female, Male(Participants) | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab | Total |
|---|---|---|---|---|
| Female | 3 | 5 | 0 | 8 |
| Male | 19 | 14 | 22 | 55 |
| Race/Ethnicity, Customized(Participants) | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 18 | 15 | 18 | 51 |
| White | 4 | 4 | 4 | 12 |
| Region of Enrollment(participants) | Ociperlimab + Tislelizumab + cCRT | Tislelizumab + cCRT | cCRT Followed by Durvalumab | Total |
|---|---|---|---|---|
| China | 17 | 12 | 16 | 45 |
| Taiwan | 1 | 3 | 2 | 6 |
| Spain | 1 | 1 | 3 | 5 |
| United States | 2 | 1 | 1 | 4 |
| Australia | 1 | 2 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jun 2021 to primary completion in Oct 2023, 28 months.
Results were first posted in Oct 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Ociperlimab
Carcinoma, Non-Small-Cell Lung →